8-K filed Sep 10, 2026 at 06:02 ET
Axogen announced a $200M cash acquisition of BioCircuit Technologies (NerveTape sutureless nerve repair device) and simultaneously priced a ~$208.7M common stock offering (4.91M shares at $42.50/sh) to fund the deal. The acquisition adds a differentiated, FDA-cleared sutureless nerve repair platform expected to be accretive to revenue growth, adjusted EBITDA margin, and adjusted EPS in year one while Axogen remains free cash flow positive. The offering closes Sept 11, 2026; the acquisition is expected to close in Q4 2026 subject to customary conditions including BioCircuit's electronics business spin-out.